Статья
АЛКОГОЛЬНАЯ КАРДИОМИОПАТИЯ: ОСНОВНЫЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ, ПАТОГЕНЕЗА И ЛЕКАРСТВЕННОЙ ТЕРАПИИ
Представлены данные по эпидемиологии и патогенезу алкогольной кардиомиопатии (АКМП), освещены особенности клинических проявлений, а также проблема ведения таких пациентов. Отдельно рассматривается психотропная терапия, направленная на снижение мотивации к употреблению алкоголя у пациентов с АКМП.
1. WHO to meet beverage company representatives to discuss health-related alcohol issues. Available at: http://www.who.int/mediacentre/news/releases/2003/pr6/en/. Accessed by 10.12.2014.
2. The physician’s guide to helping patients with alcohol problems. National Institutes of Health publication no. 95-3769. Washington DC: U.S. Department of Health and Human Services; 1995.
3. Nutrition and your health: dietary guidelines for Americans. 4th ed. Home and Garden Bulletin. Washington DC: U.S. Department of Health and Human Services, Department of Agriculture (USDA); 1995.
4. Saremi A, Arora R. The cardiovascular implications of alcohol and red wine. Am J Ther 2008; 15(3):265-77.
5. Schukit MA. ed. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. NewYork, NY: Plenum Medical Book Company; 1995.
6. Schorling JB, Buchsbaum DG. Screening for alcohol and drug abuse. Med Clin North Am 1997;81:845-65.
7. Popova S, Rehm J, Patra J. Comparing alcohol consumption in central and eastern Europe to other European countries. Alcohol and Alcoholism 2007;42 (5):465-73.
8. Anderson P, Baumberg B, eds. Alcohol in Europe: a public health persepctive. A report for the European Commission. Luxembourg: European Communities; 2006.
9. Leon DA, Chenet L, Shkolnikov VM, et al. Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? Lancet 1997; 350(9075): 383-8.
10. Zatonski WA, Jha P. The Health Transformation in Eastern Europe After 1990: A Second Look. Warsaw: Marie Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; 2000.
11. Iluk RD, RybakovaKV, Kiselev AS et al. Epidemiology and medico-social characteristics depending on beer and spirits. Zhurnal Nevrologii i Psikhiatrii 2011; (11): 3-13. Russian (Илюк Р. Д.,Рыбакова К.В., Киселёв А. С. И др. Эпидемиология и медико-социальные особенности зависимости от пива и крепких алкогольных напитков. Журнал Неврологии и Психиатрии 2011;(11): 3-13).
12. Healthcare in Russia, in 2013. Statistical collection. Moscow: Rosstat; 2013. Russian (Здравоохранение в России, 2013. Статистический сборник. Москва: Росстат; 2013).
13. Koshkina EA, Kirzhanova VV, Guseva OI, et al. Providing drug treatment population of the Russian Federation in 2012. Voprosy Narkologii 2013; (4): 3-18. Russian (Кошкина Е.А., Киржанова В.В., Гусева О.И. и др. Оказание наркологической помощи населению российской федерации в 2012 г. Вопросы Наркологии 2013; (4): 3-18).
14. Hookana E, Junttila MJ, Puurunen VP, et al. Causes of nonischemic sudden cardiac death in the current era. Heart rhythm: the official journal of the Heart Rhythm Society 2011;8:1570-5.
15. Vital and Health Statistics, October 1995; 13 (122). Hyattsville, MD: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention; 1995.
16. Fauchier L, Babuty D, Poret P. et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000;21:306-14.
17. McKenna CJ, Codd MB, McCann HA et al. Alcohol consumption idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135: 833-7.
18. Gavazzi A, De Maria R, Parolini M et al. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol2000; 85: 1114-8.
19. Fernández-SolàJ, Estruch R, Nicolás J-M et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80: 481-5.
20. Rehm J, Sempos C, Trevisan M. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease–a review. Journal of Cardiovascular Risk 2003; 10: 15-20.
21. Skotzko CE, Vrinceanu A, Krueger L, et al. Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking. Heart Fail Rev 2009; 14(1): 51-5.
22. Pavlova LI. Effect of alcohol on the occurrence of coronary heart disease. Lechashchiy Vrach 1998; (5): 5-7. Russian (Павлова Л. И. Влияние алкоголя на возникновение ишемической болезни сердца. Лечащий Врач 1998;(5): 5-7).
23. Kupari M, Koskinen P, Suokas A, et al. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66: 1473-7 .
24. Lazarevic AM, Nakatani S, Neskovic AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35:1599-606.
25. Askanas A, Udoshi M, Sadjadi SA. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980;99: 9-16.
26. Silberbauer K, Juhasz M, Ohrenberger G. et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in young alcoholics. Cardiology 1988; 75: 431-9.
27. Mathews EC, Gradin JM, Henry WL et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47: 570-8
28. Urbano-Márquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-15.
29. Moiseyev VS, Shelepin AA. Alcohol and heart disease: a guide. Moscow: GEOTAR Media; 2009. Russian (Моисеев В.С., Шелепин А.А. Алкоголь и болезни сердца: руководство. М.: ГЭОТАР-Медиа; 2009).
30. Meehan, J, Piano, MR, Solaro, RJ, et al.Heavy long-term ethanol consumption induces an α- to β-myosin heavy chain isoforms transition in rat. Basic Res Cardiol 1999; 94: 481-8.
31. Law BA, Carver WE. Activation of cardiac fibroblasts by ethanol is blocked by TGF-βinhibition. Alcohol Clin Exp Res 2013;37(8):1286-94.
32. Zhang RH, Gao JY, Guo HT. Inhibition of CYP2E1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction and apoptosis. Biochim BiophysActa 2013; 1832(1): 128-41.
33. Chen DB, Wang L, Wang PH. Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 2000; 67: 1683-93.
34. Hu C, Ge F, Hyodo E. Chronic ethanol consumption increases cardiomyocyte fatty acid uptake and decreases ventricular contractile function in C57BL/6J mice. J Mol Cell Cardiol 2013; 59: 30-40.
35. Dancy M, Leech G, Bland JM et al. Preclinical left ventricular abnormalities in alcoholic are independent of nutritional status, cirrhosis and cigarette smoking. Lancet1985;1:1122-5.
36. Astashkina OG, Vlasova NV The diagnostic method of death from coronary heart disease and alcoholic cardiomyopathy: Application № 2007136747. Inventions. Utility Models: e-newsletter 2008; (2). Available at: http://www1.fips.ru/Electronic_bulletin/Inventions_and_utility_models/02_08/Index_ru.htm. Accessed by 12/10/2014. Russian (Асташкина О. Г., Власова Н. В. Способ диагностики смерти от ишемической болезни сердца и алкогольной кардиомиопатии: заявка № 2007136747. Изобретения. Полезные модели: электронный бюллетень 2008; (2). Доступно на: http://www1.fips.ru/Electronic_bulletin/Inventions_and_utility_models/02_08/Index_ru.htm. Проверено 10.12.2014)
37. Smith-Warner SA, Spiegelman D, Yaun SS et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA1998;279:535-40.
38. Kino M, Imamitchi H, Morigutchi M, et al. Cardiovascular status in asymptomatic alcoholics, with reference to the level of ethanol consumption. Br Heart J 1981; 46: 545-51.
39. Kupari M, Koskinen P, Suokas A. Left ventricular size, mass and function in relation to the duration and quantity of heavy drinking in alcoholics. Am J Cardiol 1991; 67: 274-9.
40. Prazak P, Pfisterer M, Osswald S et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic cardiomyopathy. Eur Heart J1996;17:251-7.
41. George А, Figueredo VM. Alcoholic cardiomyopathy: a review. J Card Fail 2011;17(10):844-9.
42. Montalto NJ, Bean P. Use of contemporary biomarkers in the detection of chronic alcohol use. Med Sci Monit 2003; 9(12): RA285-90.
43. Sadovnikov A.I. Cirrhosis of the liver. The etiology, pathogenesis, clinical manifestations, diagnosis, treatment. Russkiy Meditsinskiy Zhurnal 2003; 5 (2): 37-42. Russian (Садовникова И.И. Циррозы печени. Вопросы этиологии, патогенеза, клиники, диагностики, лечения. Русский Медицинский Журнал 2003;5(2):37–42).
44. Enoch M.A., Goldman D. Problem Drinking and Alcoholism: Diagnosis and Treatment. Am Fam Physician 2002;65(3):441-9.
45. Hock B., Schwarz M., Domke I., et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005;100(10):1477-86.
46. Tarasova O.I., Ogurtsov P.P., Mazurchik N.V., Moiseyev V.S. Modern ofl aboratory markers of alcohol consumption. Klinicheskaya Farmakologiya i Terapiya 2007; (1): 45-50. Russian (Тарасова О.И., Огурцов П.П., Мазурчик Н.В., Моисеев В.С. Современные лабораторные маркеры употребления алкоголя. Клиническая Фармакология и Терапия 2007; (1): 45-50).
47. Proude E., Lopatko O., Lintzeris N. et al. The Treatment of Alcohol Problems. A Review of the Evidence Prepared for the Australian Government Department of Health and Ageing. Guidelines for the Treatment of Alcohol Problems. Canberra: Australian Government Department of Health and Aged Care; 2009.
48. Delanghe J.R., De Buyzere M.L. Carbohydrate deficient transferrin and forensic medicine. Clin Chim Acta 2009;406(1-2):1-7.
49. Wursthttp://alcalc.oxfordjournals.org/content/39/1/33.long - target-1 F.M., Alexson S., Wolfersdorf M. Concentration of fatty acid ethyl esters in hair of alcoholics: comparison to other biological state markers and self reported-ethanol intake. Alcohol Alcohol 2004;39(1):33-8.
50. Franzini M., Fornaciari I., Vico T. et al. High-sensitivity γ-glutamyltransferase fraction pattern in alcohol addicts and abstainers. Drug Alcohol Depend 2013;127(1-3):239-42.
51. Mariann RP. Alcoholic Cardiomyopathy: Incidence, Clinical Characteristics, and Pathophysiology. Chest 2002; 121(5): 1638-50.
52. Kinny E.L., Wright R.J., Caldwell J.W. Risk factors in alcoholic cardiomyopathy. Angiol J Vasc Dis1989;4:270-5.
53. Ilomaki J, Hajat A, Jussi Kauhanen J. Relationship between alcohol consumption and myocardial infarction among ageing men using a marginal structural model. Eur J Public Health 2012; 22 (6): 825-30.
54. Yoshimura A, Kimura M, Nakayama H et al. Efficacy of Disulfiram for the Treatment of Alcohol Dependence Assessed with a Multicenter Randomized Controlled Trial. Alcohol Clin Exp Res 2014;38(2):572-8.
55. Brennan JL, Leung JG, Gagliardi JP et al. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. Clin Pharmacol 2013; 5: 99-107.
56. Pettinati HM, Silverman BL, Battisti JJ et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res 2011;35(10):1804-11.
57. Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 2007;3(5):741-9.
58. Fucito L.M., Park A, Gulliver S.B. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry 2012;72(10):832-8.
59. Litten R.Z., Ryan M.L., Fertig J.B. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013;7(4):277-86.
60. Mason B.J., Quello S., Goodell V., et al. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial. JAMA Intern Med2014;174(1):70-7.
61. European Medicines Agency European Public Assessment Report (EPAR) for Selincro® EMEA/H/C/002583/0000. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002583/WC500140326.pdf. Accessed by 20.01.2014.
62. van den Brink W., Aubin H.J., Bladstrom A., et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013; 48(5): 570-8.
63. Mann K., Bladstrom A., Torup L. et al. Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. J Biological Psychiatry 2013; 73(8): 706-13.
64. Gual A., He Y., Torup L., van den Brink W., et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23(11): 1432-42.
65. Kranzler H.R., McKay J.R. Personalized treatment of alcohol dependence. Curr Psychiatry Rep 2012;14(5):486-93.